GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

Nazha A.; Rybicki L.; Abounader D.; Bolwell B.; Dean R.; Gerds A. T.; Jagadeesh D.; Hamilton B. K.; Hill B. T.; Kalaycio M.; Liu H.; Pohlman B.; Sobecks R.; Sekeres M. A.; Majhail N. S.

首页> 外文期刊>Bone marrow transplantation >GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

【24h】

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

机译：强度降低的同种异体造血干细胞移植后无GvHD，无复发的生存

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Bone marrow transplantation》 |2016年第12期|共2页
作者
Nazha A.; Rybicki L.; Abounader D.; Bolwell B.; Dean R.; Gerds A. T.; Jagadeesh D.; Hamilton B. K.; Hill B. T.; Kalaycio M.; Liu H.; Pohlman B.; Sobecks R.; Sekeres M. A.; Majhail N. S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies [J] . Nazha A., Rybicki L., Abounader D., Bone marrow transplantation . 2016,第12期

机译：强度降低的同种异体造血干细胞移植后无GvHD，无复发的生存
2. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia [J] . Zhao Yanmin, Wang Jiasheng, Luo Yi, Annals of hematology . 2017,第8期

机译：增强强度的同种异体造血干细胞移植联合伊马替尼在慢性骨髓白血病的年轻患者中的长期伊马替尼治疗具有相当的无事故存活和总生存期
3. Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies [J] . Schneidawind Dominik, Federmann Birgit, Buechele Corina, Annals of hematology . 2016,第1期

机译：氟达拉滨和白消安降低强度的条件用于老年或体弱性晚期髓系恶性肿瘤患者的异基因造血细胞移植
4. Intravenous Busulfan Reduces Toxicity Associated with Myeloablative Allogeneic Hematopoietic Transplantation in Patients with Myeloid Malignancies [C] . A. Shimoni, B. Bxelorai, I. Hardan, European Haematology Association . 2002

机译：静脉内的伯鲁兰减少骨髓恶性肿瘤患者患有髓鞘异产造血移植的毒性
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood [O] . Changcheng Zheng, Xiaoyu Zhu, Baolin Tang, 2018

机译：慢性髓样白血病的青少年和年轻人中无关脐带血或同种异体外周血干细胞/骨髓的移植：具有可比的结果但脐带血幸存者的慢性无GVHD和无复发生存率更高
7. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies [O] . A Nazha, L Rybicki, D Abounader, 2016

机译：在骨髓恶性肿瘤患者的老年患者中减少强度异种造血细胞移植后的GVHD，复发存活

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

著录项

相似文献

相关主题

期刊订阅